LAM561

LAM561 is a small-molecule drug developed by Laminar Pharmaceuticals. Its target is MET (the sponsor names membrane lipids). The sponsor states: A hydroxylated lipid derivative that targets membrane lipids and induces cytocidal autophagy in cancer models; in Phase 2b/3 testing for newly diagnosed, MGMT-methylated glioblastoma. ClinicalTrials.gov describes the intervention as: Once a patient is allocated a dose of LAM561, they will receive the same dose on a daily basis in treatment cycles of 21 days (3 weeks), which may be repeated without therapy interruption until a criterion for discontinuation (clinical or r. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT04250922 (LAM561 With RT and TMZ for Adults With Glioblastoma), in glioma & glioblastoma. The largest, NCT04250922, plans to enrol 144 participants (actual) with primary completion was scheduled for 2026-01-15 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.